Overexpression of BP1, a homeobox gene, is associated with resistance to all-trans retinoic acid in acute promyelocytic leukemia cells

Rania T. Awwad, Khanh Do, Holly Stevenson, Sidney W. Fu, Francesco Lo-Coco, Maura Costello, Cassandra L. Campbell, Patricia E. Berg

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

BP1, a homeobox gene, is overexpressed in the bone marrow of 63% of acute myeloid leukemia patients. In this study, we compared the growth-inhibitory and cyto-differentiating activities of all-trans retinoic acid (ATRA) in NB4 (ATRA-responsive) and R4 (ATRA-resistant) acute promyelocytic leukemia (APL) cells relative to BP1 levels. Expression of two oncogenes, bcl-2 and c-myc, was also assessed. NB4 and R4 cells express BP1, bcl-2, and c-myc; the expression of all three genes was repressed after ATRA treatment of NB4 cells but not R4 cells. To determine whether BP1 overexpression affects sensitivity to ATRA, NB4 cells were transfected with a BP1-expressing plasmid and treated with ATRA. In cells overexpressing BP1: (1) proliferation was no longer inhibited; (2) differentiation was reduced two- to threefold; (3) c-myc was no longer repressed. These and other data suggest that BP1 may regulate bcl-2 and c-myc expression. Clinically, BP1 levels were elevated in all pretreatment APL patients tested, while BP1 expression was decreased in 91% of patients after combined ATRA and chemotherapy treatment. Two patients underwent disease relapse during follow-up; one patient exhibited a 42-fold increase in BP1 expression, while the other showed no change. This suggests that BP1 may be part of a pathway involved in resistance to therapy. Taken together, our data suggest that BP1 is a potential therapeutic target in APL.

Original languageEnglish
Pages (from-to)195-203
Number of pages9
JournalAnnals of Hematology
Volume87
Issue number3
DOIs
Publication statusPublished - Mar 2008

Fingerprint

Acute Promyelocytic Leukemia
Homeobox Genes
Tretinoin
Therapeutics
Oncogenes
Acute Myeloid Leukemia
Plasmids
Bone Marrow
Recurrence
Drug Therapy
Growth
Genes

Keywords

  • Acute promyelocytic leukemia
  • All-trans retinoic acid
  • BP1
  • Homeobox

ASJC Scopus subject areas

  • Hematology

Cite this

Overexpression of BP1, a homeobox gene, is associated with resistance to all-trans retinoic acid in acute promyelocytic leukemia cells. / Awwad, Rania T.; Do, Khanh; Stevenson, Holly; Fu, Sidney W.; Lo-Coco, Francesco; Costello, Maura; Campbell, Cassandra L.; Berg, Patricia E.

In: Annals of Hematology, Vol. 87, No. 3, 03.2008, p. 195-203.

Research output: Contribution to journalArticle

Awwad, Rania T. ; Do, Khanh ; Stevenson, Holly ; Fu, Sidney W. ; Lo-Coco, Francesco ; Costello, Maura ; Campbell, Cassandra L. ; Berg, Patricia E. / Overexpression of BP1, a homeobox gene, is associated with resistance to all-trans retinoic acid in acute promyelocytic leukemia cells. In: Annals of Hematology. 2008 ; Vol. 87, No. 3. pp. 195-203.
@article{22cf15857e884b14a9f51a2f108ec99a,
title = "Overexpression of BP1, a homeobox gene, is associated with resistance to all-trans retinoic acid in acute promyelocytic leukemia cells",
abstract = "BP1, a homeobox gene, is overexpressed in the bone marrow of 63{\%} of acute myeloid leukemia patients. In this study, we compared the growth-inhibitory and cyto-differentiating activities of all-trans retinoic acid (ATRA) in NB4 (ATRA-responsive) and R4 (ATRA-resistant) acute promyelocytic leukemia (APL) cells relative to BP1 levels. Expression of two oncogenes, bcl-2 and c-myc, was also assessed. NB4 and R4 cells express BP1, bcl-2, and c-myc; the expression of all three genes was repressed after ATRA treatment of NB4 cells but not R4 cells. To determine whether BP1 overexpression affects sensitivity to ATRA, NB4 cells were transfected with a BP1-expressing plasmid and treated with ATRA. In cells overexpressing BP1: (1) proliferation was no longer inhibited; (2) differentiation was reduced two- to threefold; (3) c-myc was no longer repressed. These and other data suggest that BP1 may regulate bcl-2 and c-myc expression. Clinically, BP1 levels were elevated in all pretreatment APL patients tested, while BP1 expression was decreased in 91{\%} of patients after combined ATRA and chemotherapy treatment. Two patients underwent disease relapse during follow-up; one patient exhibited a 42-fold increase in BP1 expression, while the other showed no change. This suggests that BP1 may be part of a pathway involved in resistance to therapy. Taken together, our data suggest that BP1 is a potential therapeutic target in APL.",
keywords = "Acute promyelocytic leukemia, All-trans retinoic acid, BP1, Homeobox",
author = "Awwad, {Rania T.} and Khanh Do and Holly Stevenson and Fu, {Sidney W.} and Francesco Lo-Coco and Maura Costello and Campbell, {Cassandra L.} and Berg, {Patricia E.}",
year = "2008",
month = "3",
doi = "10.1007/s00277-007-0402-7",
language = "English",
volume = "87",
pages = "195--203",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Overexpression of BP1, a homeobox gene, is associated with resistance to all-trans retinoic acid in acute promyelocytic leukemia cells

AU - Awwad, Rania T.

AU - Do, Khanh

AU - Stevenson, Holly

AU - Fu, Sidney W.

AU - Lo-Coco, Francesco

AU - Costello, Maura

AU - Campbell, Cassandra L.

AU - Berg, Patricia E.

PY - 2008/3

Y1 - 2008/3

N2 - BP1, a homeobox gene, is overexpressed in the bone marrow of 63% of acute myeloid leukemia patients. In this study, we compared the growth-inhibitory and cyto-differentiating activities of all-trans retinoic acid (ATRA) in NB4 (ATRA-responsive) and R4 (ATRA-resistant) acute promyelocytic leukemia (APL) cells relative to BP1 levels. Expression of two oncogenes, bcl-2 and c-myc, was also assessed. NB4 and R4 cells express BP1, bcl-2, and c-myc; the expression of all three genes was repressed after ATRA treatment of NB4 cells but not R4 cells. To determine whether BP1 overexpression affects sensitivity to ATRA, NB4 cells were transfected with a BP1-expressing plasmid and treated with ATRA. In cells overexpressing BP1: (1) proliferation was no longer inhibited; (2) differentiation was reduced two- to threefold; (3) c-myc was no longer repressed. These and other data suggest that BP1 may regulate bcl-2 and c-myc expression. Clinically, BP1 levels were elevated in all pretreatment APL patients tested, while BP1 expression was decreased in 91% of patients after combined ATRA and chemotherapy treatment. Two patients underwent disease relapse during follow-up; one patient exhibited a 42-fold increase in BP1 expression, while the other showed no change. This suggests that BP1 may be part of a pathway involved in resistance to therapy. Taken together, our data suggest that BP1 is a potential therapeutic target in APL.

AB - BP1, a homeobox gene, is overexpressed in the bone marrow of 63% of acute myeloid leukemia patients. In this study, we compared the growth-inhibitory and cyto-differentiating activities of all-trans retinoic acid (ATRA) in NB4 (ATRA-responsive) and R4 (ATRA-resistant) acute promyelocytic leukemia (APL) cells relative to BP1 levels. Expression of two oncogenes, bcl-2 and c-myc, was also assessed. NB4 and R4 cells express BP1, bcl-2, and c-myc; the expression of all three genes was repressed after ATRA treatment of NB4 cells but not R4 cells. To determine whether BP1 overexpression affects sensitivity to ATRA, NB4 cells were transfected with a BP1-expressing plasmid and treated with ATRA. In cells overexpressing BP1: (1) proliferation was no longer inhibited; (2) differentiation was reduced two- to threefold; (3) c-myc was no longer repressed. These and other data suggest that BP1 may regulate bcl-2 and c-myc expression. Clinically, BP1 levels were elevated in all pretreatment APL patients tested, while BP1 expression was decreased in 91% of patients after combined ATRA and chemotherapy treatment. Two patients underwent disease relapse during follow-up; one patient exhibited a 42-fold increase in BP1 expression, while the other showed no change. This suggests that BP1 may be part of a pathway involved in resistance to therapy. Taken together, our data suggest that BP1 is a potential therapeutic target in APL.

KW - Acute promyelocytic leukemia

KW - All-trans retinoic acid

KW - BP1

KW - Homeobox

UR - http://www.scopus.com/inward/record.url?scp=38649121797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38649121797&partnerID=8YFLogxK

U2 - 10.1007/s00277-007-0402-7

DO - 10.1007/s00277-007-0402-7

M3 - Article

VL - 87

SP - 195

EP - 203

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 3

ER -